10 key snapshots from day 2 of EMAS!

1. 15% of all cancer deaths are due to breast cancer, with the risk as high as 1 in 8 in the US. Data shows that women who are on MHT have a better prognosis after diagnosis than those who are not taking hormone treatment

2. MHT is effective in both primary and secondary prevention of CVD, resulting in up to a 50% reduction in CVD events

3. The risk of breast cancer increases with daily drinking and obesity whilst exercise can combat risk, this highlights the importance of discussing MHT risk with patients

4. Latest data shows that in high grade ovarian cancer, MHT does not increase risk of re-occurrence or mortality but low grade ovarian cancers such as sarcoma are considered a contraindication to MHT

5. Migraines are the 3rd biggest disabling condition in women worldwide, the perimenopausal phase is said to carry the highest migraine burden and a phase III clinical trial is being carried out on an antibody to the CGRP receptor with hope it could treat both migraines and hot flushes

6. PMS related suicides have been reported and the condition should not be ignored, particularly as it becomes more prevalent in the perimenopausal phase. Data suggests MHT should be used in preference to SSRIs in this phase

7. Genome wide association studies have been used to identify genes involved with slowing down and accelerating menopause. Results show ovarian function seems to play an important role in DNA maintenance and repair.

8. Arthralgia is reported by over 50% of women in the perimenopausal phase, they are susceptible to risk of osteoarthritis (particularly of the hand) and rheumatoid arthritis

9. Data has shown that the use of MHT in healthy BRCA1 and BRCA2 carriers is not associated with risk of breast, ovarian or endometrial cancers

10. Results reveal there is an increased risk of death in women who experience menopause early under the age of 45, MHT is an essential treatment in these circumstances.